Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

ACT for CP Individual Patient Expanded Access IND Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03203941
Expanded Access Status : No longer available
First Posted : June 29, 2017
Last Update Posted : March 1, 2019
Sponsor:
Information provided by (Responsible Party):
Charles Cox, The University of Texas Health Science Center, Houston

Brief Summary:
Individual patient expanded access protocol for a child with cerebral palsy (CP) who has autologous umbilical cord blood available and who is ineligible to participate in other stem cell studies for children with CP.

Condition or disease Intervention/treatment
Cerebral Palsy Biological: Autologous Cord Blood Stem Cells

Detailed Description:
This protocol is part of an FDA Individual Patient Expanded Access IND submitted at the request of the parents of a child with cerebral palsy (CP) who is ineligible to participate in other stem cell studies. For this child, there are no other treatment options.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients, Treatment IND/Protocol
Official Title: Autologous Cell Therapies for Cerebral Palsy-Chronic (ACT for CP) Individual Patient Expanded Access IND Protocol

Resource links provided by the National Library of Medicine



Intervention Details:
  • Biological: Autologous Cord Blood Stem Cells
    This is an individual patient expanded access protocol.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Criteria

Inclusion Criteria:

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03203941


Locations
Layout table for location information
United States, Texas
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
Charles Cox
Investigators
Layout table for investigator information
Principal Investigator: Charles S Cox, MD UTHealth, McGovern Medical School at Houston

Layout table for additonal information
Responsible Party: Charles Cox, The George and Cynthia Mitchell Distinguished Chair in Neurosciences Director, Children's Program in Regenerative Medicine Professor, Department of Pediatric Surgery UTHealth McGovern Medical School at Houston, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT03203941     History of Changes
Other Study ID Numbers: HSC-MS-17-0529
First Posted: June 29, 2017    Key Record Dates
Last Update Posted: March 1, 2019
Last Verified: February 2019

Keywords provided by Charles Cox, The University of Texas Health Science Center, Houston:
Autologous Cord Blood Stem Cells

Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebral Palsy
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases